A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

Last updated: January 31, 2025
Sponsor: Bristol-Myers Squibb
Overall Status: Active - Recruiting

Phase

N/A

Condition

Rosacea

Skin Wounds

Warts

Treatment

Deucravacitinib

Clinical Study ID

NCT06512337
IM011-1180
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participant aged 18 years or older

  • Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with BodySurface Area ≥ 3% and < 10%

  • Participant newly initiated deucravacitinib according to the label

  • Provided written informed consent to participate in the study

Exclusion

Exclusion Criteria:

  • Participating in or planning to participate in an interventional clinical trial

  • Concomitant use of other systemic treatments for psoriasis at baseline

  • Prior treatment of deucravacitinib

Study Design

Total Participants: 150
Treatment Group(s): 1
Primary Treatment: Deucravacitinib
Phase:
Study Start date:
January 20, 2025
Estimated Completion Date:
August 31, 2026

Connect with a study center

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong 510091
    China

    Active - Recruiting

  • Local Institution - 0001

    Guangzhou, Guangdong 510091
    China

    Site Not Available

  • Hangzhou Tigermed Consulting Co., Ltd.

    HangZhou,
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.